Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Copeland

Showing results (381-390 of 449) with videos related to

Pageof 45
Sort By:
Elife|August 7, 2023
Decoupled neoantigen cross-presentation by dendritic cells limits anti-tumor immunity against tumors with heterogeneous neoantigen expressionKim Bich Nguyen, Malte Roerden, Christopher J Copeland, et al.
Gynecologic Oncology|July 1, 1992
The prognostic implications of low serum CA 125 levels prior to the second-look operation for stage III and IV epithelial ovarian cancerH H Gallion, J E Hunter, J R van Nagell, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 22, 2001
Phase I trial of escalating doses of paclitaxel combined with fixed doses of cisplatin and doxorubicin in advanced endometrial cancer and other gynecologic malignancies: a Gynecologic Oncology Group studyG F Fleming, J M Fowler, S E Waggoner, et al.
Gynecologic Oncology|August 28, 2023
Prevalence of type 2 diabetes diagnoses in the perioperative and survivorship periods following surgical management of endometrial cancer: An opportunity for screening and intervention?Molly Morton, Eric M McLaughlin, Corinne A Calo, et al.
Gynecologic Oncology Reports|April 21, 2023
Recurrence rate in early-stage epithelial ovarian cancer: Is there a role for upfront maintenance with PARP inhibitors in stages I and II?Monica D Levine, David M O'Malley, Paulina J Haight, et al.
Gynecologic Oncology|July 26, 2005
Implications of second-look laparotomy in the context of optimally resected stage III ovarian cancer: a non-randomized comparison using an explanatory analysis: a Gynecologic Oncology Group studyBenjamin E Greer, Brian N Bundy, Robert F Ozols, et al.
BMC Cancer|November 24, 2022
Co-designed weight management intervention for women recovering from oestrogen-receptor positive breast cancerJ M Saxton, K Pickering, S Wane, et al.
The Journal of Biological Chemistry|June 25, 2002
Characterization of a heparan sulfate octasaccharide that binds to herpes simplex virus type 1 glycoprotein DJian Liu, Zach Shriver, R Marshall Pope, et al.
Gynecologic Oncology|April 3, 2026
Evaluation of immunotherapy response in the radiated field in patients with recurrent endometrial and cervical cancerJulia Chalif, Molly Morton, Anna Gonzalez, et al.
Gynecologic Oncology|June 5, 2024
Retraction notice to "Cost-effectiveness of chemotherapy and dostarlimab for advanced or recurrent endometrial cancer" [Gynecologic Oncology 183 (2024) 78-84]Courtney J Riedinger, David A Barrington, Christa I Nagel, et al.
Pageof 45

Showing results (381-390 of 449) with videos related to

Sort By:
Pageof 45
Elife|August 7, 2023
Decoupled neoantigen cross-presentation by dendritic cells limits anti-tumor immunity against tumors with heterogeneous neoantigen expressionKim Bich Nguyen, Malte Roerden, Christopher J Copeland, et al.
Gynecologic Oncology|July 1, 1992
The prognostic implications of low serum CA 125 levels prior to the second-look operation for stage III and IV epithelial ovarian cancerH H Gallion, J E Hunter, J R van Nagell, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 22, 2001
Phase I trial of escalating doses of paclitaxel combined with fixed doses of cisplatin and doxorubicin in advanced endometrial cancer and other gynecologic malignancies: a Gynecologic Oncology Group studyG F Fleming, J M Fowler, S E Waggoner, et al.
Gynecologic Oncology|August 28, 2023
Prevalence of type 2 diabetes diagnoses in the perioperative and survivorship periods following surgical management of endometrial cancer: An opportunity for screening and intervention?Molly Morton, Eric M McLaughlin, Corinne A Calo, et al.
Gynecologic Oncology Reports|April 21, 2023
Recurrence rate in early-stage epithelial ovarian cancer: Is there a role for upfront maintenance with PARP inhibitors in stages I and II?Monica D Levine, David M O'Malley, Paulina J Haight, et al.
Gynecologic Oncology|July 26, 2005
Implications of second-look laparotomy in the context of optimally resected stage III ovarian cancer: a non-randomized comparison using an explanatory analysis: a Gynecologic Oncology Group studyBenjamin E Greer, Brian N Bundy, Robert F Ozols, et al.
BMC Cancer|November 24, 2022
Co-designed weight management intervention for women recovering from oestrogen-receptor positive breast cancerJ M Saxton, K Pickering, S Wane, et al.
The Journal of Biological Chemistry|June 25, 2002
Characterization of a heparan sulfate octasaccharide that binds to herpes simplex virus type 1 glycoprotein DJian Liu, Zach Shriver, R Marshall Pope, et al.
Gynecologic Oncology|April 3, 2026
Evaluation of immunotherapy response in the radiated field in patients with recurrent endometrial and cervical cancerJulia Chalif, Molly Morton, Anna Gonzalez, et al.
Gynecologic Oncology|June 5, 2024
Retraction notice to "Cost-effectiveness of chemotherapy and dostarlimab for advanced or recurrent endometrial cancer" [Gynecologic Oncology 183 (2024) 78-84]Courtney J Riedinger, David A Barrington, Christa I Nagel, et al.
Pageof 45